Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)

Stopped Forced to close study due to poor recruitment (company withdrew drug support).

Conditions

• Graft Versus Host Disease
• JNS Kinase
• Topical Administration

Interventions

• DRUG: Ruxolitinib 1.5% cream
• DRUG: vehicle cream

Sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)